Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.51 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283828 | 0.84 | FFAR1 (0.57) | MAPTHPGDRAB9AMAOBMAOA | |
| SCHEMBL30356696 | 0.84 | MAOB (0.58) | MAPTHPGDRAB9AMAOBMAOA | |
| SCHEMBL11548018 | 0.84 | MAOB (0.58) | MAPTHPGDRAB9AMAOBMAOA | |
| SCHEMBL11544485 | 0.84 | SCN9A (0.46) | SCN9AFPR2IGFBP3LMNASMN1; SMN2 | |
| SCHEMBL753409 | 0.82 | SCN9A (0.44) | MAPTHPGDSCN9AFPR2IGFBP3 | |
| SCHEMBL2544053 | 0.82 | SCN9A (0.44) | MAPTHPGDSCN9AFPR2IGFBP3 | |
| SCHEMBL2964396 | 0.82 | MAPT (0.66) | MAPTHPGDRAB9AMAOBMAOA | |
| SCHEMBL9762032 | 0.82 | MAPT (0.53) | MAPTHPGDRAB9AIGFBP3MAOB | |
| SCHEMBL11540797 | 0.82 | SCN9A (0.46) | SCN9AFPR2IGFBP3LMNASMN1; SMN2 | |
| SCHEMBL3366867 | 0.81 | ALDH1A1 (0.55) | MAPTHPGDRAB9AIGFBP3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2188254-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | MAPT 3258/4885HPGD 587/4885RAB9A 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.